A landmark in our mission to enable cell therapy manufacture at scale. This week, we celebrated the arrival of the Constellation robotic platform to Cell and Gene Therapy Catapult Digital and Automation Testbeds facility.
Cellular Origins has installed our first Constellation platform. The testbeds, located at Cell and Gene Therapy Catapult’s Stevenage Manufacturing Innovation Centre, are among the first sandbox environments in the world that have been specifically designed with automation, digital and robotic technologies for the cell and gene therapy industry.
Our robots’ new home, in the Cell and Gene Therapy Catapult Digital and Automation Testbeds, will not only showcase our system in a clean room environment, but be put through its paces in operational and biological testing, and integrated with other manufacturing digital solutions.
This is pushing the boundaries of automation in cell and gene therapy manufacturing, and bringing industrialisation of our industry a step closer. The facility opens soon, providing the opportunity to see our technology in the robot-flesh.
Edwin Stone, CEO, Cellular Origins, states “This installation at the Cell and Gene Therapy Catapult marks the first delivery of a Constellation system to a customer facility. This is both a landmark for Cellular Origins, and a step forward in unlocking the potential of cell therapies by overcoming the manufacturing challenges that have held back the industry to date. I’m delighted to be working with the experts at the Cell and Gene Therapy Catapult to advance the industry to the benefit of all those who can benefit from the ability to scale cell therapies.”
Matthew Durdy, Chief Executive at the Cell and Gene Therapy Catapult, states “Embracing automation is a key step that the cell and gene therapy industry must take to reduce costs, increase efficiency and meet the growing demand for advanced therapies. Through working with leading robotics and software experts such as Cellular Origins and Autolomous, we aim to develop new strategies that increase levels of automation. This will help our collaborators access the benefits of these technologies, help make advanced therapies more affordable to healthcare systems, and help more patients receive life changing therapies.”